STAA - הכנסה תפעולית לפני ניכוי פחת STAAR Surgical

A focus on material biocompatibility and the minimization of defects ensures business stability for STAAR Surgical Company (STAA). The company's aggregate EBITDA on the chart confirms this trend, where 32.89 characterizes this valuation parameter. Dominance in the implant niche is supported by Collamer patents and the complexity of physician training. An expansion strategy in Asia and a focus on youth via a safe alternative to laser vision correction are driving growth.

STAAR Surgical Company (STAA) maintains its monopoly position in the EVO ICL implantable lens segment through the active implementation of innovations in refractive surgery. This indicator measures net cash flow from operating activities, excluding the impact of depreciation and tax liabilities. The metric allows for an assessment of the business's actual ability to act as a cash generator to fund its R&D pipeline. Growth in this indicator confirms the effectiveness of new product commercialization. The price action of the EBITDA reflects the resilience of the operating model.